Clinical trial
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast…
NCT00105950 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00105950 |
|---|---|
| Title | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer |
| Official title | A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 126 |
| Start date | Mar 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | May 1, 2010 |
| First posted | Mar 21, 2005 |
| Last update posted | Sep 28, 2015 |
| Countries | Belgium, Canada, France, Israel, Spain, Tunisia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: